FLINT, Mich., Oct. 22, 2015 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO) announced that it has secured the ability to dispense Coagadex (coagulation factor X, human) to its patients from Bio Products Laboratory Limited (BPL), a leading manufacturer of plasma-derived protein therapies. Coagadex was approved by the U.S. Food and Drug Administration (FDA) on Oct. 20, 2015. Coagadex is the first and only FDA-approved product to treat hereditary factor X deficiency, and is the only factor X concentrate available in the U.S.
Factor X ("ten") deficiency is a rare, inherited bleeding disorder caused by inadequate levels of clotting factor X protein in the blood. Similar to hemophilia A and hemophilia B, factor X deficiency is characterized by episodes of prolonged spontaneous bleeding. As one of the rarest bleeding disorders, it affects approximately 300 to 600 patients in the U.S. The goal of treatment in patients with hereditary factor X deficiency is to replace their missing factor X without adding other clotting factors the patients do not need.
"We are pleased to be selected as a provider of Coagadex," said Phil Hagerman, chairman and CEO of Diplomat. "Diplomat and its specialty infusion companies, AHF, BioRx and MedPro Rx, are strong supporters of the bleeding disorders community. We are excited to work with BPL to deliver a highly specialized home treatment option for patients with this rare bleeding disorder."
In an effort to promote a high level of service to this patient community, BPL will provide specialized disease state and Coagadex product training to Diplomat employees.
Diplomat and its affiliate companies expect to begin distribution of Coagadex in December 2015.
Please see the full prescribing information for Coagadex at www.coagadex.com.
To learn more about Diplomat, visit www.diplomat.is.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients, and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Kali Lucas, Public Relations Coordinator
810.768.9580 | [email protected]
Gary Rice, RPh, MS, MBA, CSP,
Vice President, Clinical Services
810.768.9863 | [email protected]
SOURCE Diplomat Pharmacy, Inc.